Core Laboratories Valuation
| CLB Stock | USD 19.61 0.03 0.15% |
At this time, the firm appears to be overvalued. Core Laboratories shows a prevailing Real Value of $17.09 per share. The current price of the firm is $19.61. Our model approximates the value of Core Laboratories from analyzing the firm fundamentals such as Profit Margin of 0.06 %, return on equity of 0.12, and Current Valuation of 1.05 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Core Laboratories' valuation include:
Price Book 3.3531 | Enterprise Value | Enterprise Value Ebitda 15.1367 | Price Sales 1.7797 | Forward PE 19.7628 |
Overvalued
Today
Please note that Core Laboratories' price fluctuation is not too volatile at this time. Calculation of the real value of Core Laboratories is based on 3 months time horizon. Increasing Core Laboratories' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Core Laboratories is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Core Stock. However, Core Laboratories' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.61 | Real 17.09 | Target 15.83 | Hype 19.92 | Naive 18.74 |
The real value of Core Stock, also known as its intrinsic value, is the underlying worth of Core Laboratories Company, which is reflected in its stock price. It is based on Core Laboratories' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Core Laboratories' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Core Laboratories NV helps investors to forecast how Core stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Core Laboratories more accurately as focusing exclusively on Core Laboratories' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Core Laboratories' intrinsic value based on its ongoing forecasts of Core Laboratories' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Core Laboratories' closest peers. If more than one evaluation category is relevant for Core Laboratories we suggest using both methods to arrive at a better estimate.
Core Laboratories Cash |
|
Core Revenue by Product
Core Laboratories Total Value Analysis
Core Laboratories NV is currently expected to have company total value of 1.05 B with market capitalization of 921 M, debt of 180.14 M, and cash on hands of 19.16 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Core Laboratories fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.05 B | 921 M | 180.14 M | 19.16 M |
Core Laboratories Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Core Laboratories was currently reported as 5.89. The company has Price/Earnings To Growth (PEG) ratio of 1.67. Core Laboratories last dividend was issued on the 3rd of November 2025. The entity had 2:1 split on the 9th of July 2010. Based on the key indicators related to Core Laboratories' liquidity, profitability, solvency, and operating efficiency, Core Laboratories NV is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 110 M | 64.8 M |
|
|
Core Laboratories Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Core Laboratories has an asset utilization ratio of 88.73 percent. This suggests that the Company is making $0.89 for each dollar of assets. An increasing asset utilization means that Core Laboratories NV is more efficient with each dollar of assets it utilizes for everyday operations.Core Laboratories Profitability Analysis
Based on Core Laboratories' profitability indicators, Core Laboratories NV is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in March. Profitability indicators assess Core Laboratories' ability to earn profits and add value for shareholders.Net Income | First Reported 1995-03-31 | Previous Quarter 10.6 M | Current Value 14.2 M | Quarterly Volatility 22.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.2 | 0.15 |
|
|
For Core Laboratories profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Core Laboratories to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Core Laboratories utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Core Laboratories's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Core Laboratories over time as well as its relative position and ranking within its peers.
Core Laboratories Earnings per Share Projection vs Actual
By analyzing Core Laboratories' earnings estimates, investors can diagnose different trends across Core Laboratories' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Core Laboratories NV is based on EPS before non-recurring items and includes expenses related to employee stock options.Core Laboratories Ownership Allocation
The majority of Core Laboratories NV outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Core Laboratories to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Core Laboratories. Please pay attention to any change in the institutional holdings of Core Laboratories NV as this could imply that something significant has changed or is about to change at the company. Please note that on January 14, 2019, Representative Thomas J Rooney of US Congress acquired $15k to $50k worth of Core Laboratories's common stock.Core Laboratories Profitability Analysis
The company reported the last year's revenue of 523.85 M. Total Income to common stockholders was 32.15 M with profit before taxes, overhead, and interest of 103.23 M.Core Laboratories Past Distributions to stockholders
| 24th of November 2025 | ||
| 25th of August 2025 | ||
| 27th of May 2025 | ||
| 3rd of March 2025 | ||
| 25th of November 2024 | ||
| 26th of August 2024 | ||
| 4th of June 2024 | ||
| 28th of May 2024 | ||
| 4th of March 2024 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Core Laboratories' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Core Laboratories and how it compares across the competition.
About Core Laboratories Valuation
The stock valuation mechanism determines Core Laboratories' current worth on a weekly basis. Our valuation model uses a comparative analysis of Core Laboratories. We calculate exposure to Core Laboratories's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Core Laboratories's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 101.6 M | 169.8 M | |
| Pretax Profit Margin | 0.08 | 0.11 | |
| Operating Profit Margin | 0.10 | 0.13 | |
| Net Profit Margin | 0.05 | 0.08 | |
| Gross Profit Margin | 0.15 | 0.20 |
Core Laboratories Quarterly Retained Earnings |
|
A single share of Core Laboratories represents a small ownership stake in the entity. As a stockholder of Core, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Core Laboratories Dividends Analysis For Valuation
The current year's Dividends Paid is expected to grow to about (1.6 M). In addition to that, Dividend Yield is expected to decline to 0. At present, Core Laboratories' Retained Earnings are projected to decrease significantly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 37.26, whereas Retained Earnings Total Equity is forecasted to decline to about 73.5 M.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | -1.7 M | -1.6 M | |
| Dividend Payout Ratio | 0.05 | 0.05 | |
| Dividend Paid And Capex Coverage Ratio | 3.41 | 1.83 |
There are various types of dividends Core Laboratories can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Core shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Core Laboratories NV directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Core pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Core Laboratories by the value of the dividends paid out.
Core Laboratories Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 47.7 M | |
| Quarterly Earnings Growth Y O Y | 0.2 | |
| Forward Price Earnings | 19.7628 |
Core Laboratories Current Valuation Indicators
Valuation refers to the process of determining the present value of Core Laboratories NV and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Core we look at many different elements of the entity such as Core's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Core Laboratories, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Core Laboratories' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Core Laboratories' worth.Complementary Tools for Core Stock analysis
When running Core Laboratories' price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |